Opioid antagonist activity of naltrexone-derived bivalent ligands: Importance of a properly oriented molecular scaffold to guide ''address'' recognition at kappa opioid receptors

被引:17
作者
Bolognesi, M
Ojala, WH
Gleason, WB
Griffin, JF
FarouzGrant, F
Larson, DL
Takemori, AE
Portoghese, PS
机构
[1] UNIV MINNESOTA,COLL PHARM,DEPT MED CHEM,MINNEAPOLIS,MN 55455
[2] UNIV MINNESOTA,SCH MED,DEPT PHARMACOL,MINNEAPOLIS,MN 55455
[3] UNIV MINNESOTA,SCH MED,CTR BIOMED ENGN,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455
[4] HAUPTMAN WOODWARD MED RES INST,BUFFALO,NY 14203
关键词
D O I
10.1021/jm950807f
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The presence of a molecular scaffold to orient a basic group is important for potent and selective kappa opioid antagonist selectivity. An attempt to determine how the geometry of the scaffold affects this selectivity has led to the synthesis of a bivalent ligand (5) whose linker constrains the N17' basic nitrogen (the ''address'') to a position that is 6.5 Angstrom from N17' in the kappa antagonist norBNI (1) when these molecules are superimposed. The fact that compound 5 was found to be a highly selective and potent mu-selective antagonist supports the idea that the position of N17' in 5 precludes effective ion pairing with the nonconserved residue Glu297 on outer loop 3 of the kappa opioid receptor. The high mu receptor binding affinity and in vitro pharmacological selectivity of 5 coupled with its presumed low central nervous system bioavailability suggest that it may be a useful antagonist for the investigation of peripheral mu opioid receptors.
引用
收藏
页码:1816 / 1822
页数:7
相关论文
共 32 条
  • [1] CHEN Y, 1993, MOL PHARMACOL, V44, P8
  • [2] SOLUTION CONFORMATIONS OF THE 6-ALPHA-EPIMER AND 6-BETA-EPIMER OF OXYMORPHAMINE
    CROUCH, RC
    BHATIA, AV
    LEVER, OW
    [J]. TETRAHEDRON LETTERS, 1983, 24 (44) : 4801 - 4804
  • [3] CLONING OF A DELTA OPIOID RECEPTOR BY FUNCTIONAL EXPRESSION
    EVANS, CJ
    KEITH, DE
    MORRISON, H
    MAGENDZO, K
    EDWARDS, RH
    [J]. SCIENCE, 1992, 258 (5090) : 1952 - 1955
  • [4] FOURNIEZALUSKI MC, 1981, MOL PHARMACOL, V20, P484
  • [5] CRYSTAL-STRUCTURES OF ALPHA-FUNALTREXAMINE AND BETA-FUNALTREXAMINE - CONFORMATIONAL REQUIREMENT OF THE FUMARAMATE MOIETY IN THE IRREVERSIBLE BLOCKAGE OF MU-OPIOID RECEPTORS
    GRIFFIN, JF
    LARSON, DL
    PORTOGHESE, PS
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1986, 29 (05) : 778 - 783
  • [6] ANALOGS OF BETA-LPH61-64 POSSESSING SELECTIVE AGONIST ACTIVITY AT MU-OPIATE RECEPTORS
    HANDA, BK
    LANE, AC
    LORD, JAH
    MORGAN, BA
    RANCE, MJ
    SMITH, CFC
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1981, 70 (04) : 531 - 540
  • [7] HENDERSON G, 1972, BRIT J PHARMACOL, V46, P746
  • [8] HJORTH SA, 1995, MOL PHARMACOL, V47, P1089
  • [9] 5-METHYLADENINE - A TRANSIENT INTERMEDIATE IN A TRANSLOCATIVE REARRANGEMENT
    HOSMANE, RS
    BAKTHAVACHALAM, V
    LEONARD, NJ
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1982, 104 (01) : 235 - 239
  • [10] JAFFE JH, 1990, PHARMACOL BASIS THER, P485